Biotech | January 07, 2022
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
Biogen paid Ionis a US $ 60 million one-time upfront payment
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Partnering to build biosynthesis processes and a pharmaceutical production platform
A toll-free helpline to be set up to help doctors and patients
Subscribe To Our Newsletter & Stay Updated
